Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression (scientific article published in April 2001)

cites work (P2860)

Q86177360	6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance
Q90020619	A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites
Q37207789	A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.
Q47336853	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation
Q37791817	A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients
Q33390197	A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state
Q47428958	A functional single nucleotide polymorphism in the tyrosinase gene promoter affects skin color and transcription activity in the black-boned chicken
Q43696961	A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications
Q35043486	A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta
Q35826448	A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
Q46529262	A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.
Q36896796	A pharmacogenomics primer
Q37161904	A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients
Q35217493	A review and assessment of potential sources of ethnic differences in drug responsiveness
Q38952230	A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients
Q44431079	A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus
Q54523852	ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Q35051318	ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
Q43598370	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients
Q30532640	Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.
Q36835902	Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia
Q34579490	Advancing the medical management of epilepsy: disease modification and pharmacogenetics
Q38183664	African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.
Q43759147	Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population
Q40433411	Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects
Q30883426	Altered splicing pattern of TACC1 mRNA in gastric cancer.
Q36544917	Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues
Q37725997	Ambient tonicity and intestinal cytochrome CYP3A.
Q37939200	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.
Q36412046	Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray
Q36475143	Analysis of pharmacogenetic traits in two distinct South African populations
Q33850686	Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
Q50548159	Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association with Cytochrome 3A (CYP3A) Polymorphisms
Q36334753	Antimycotic drug discovery in the age of genomics
Q53278594	Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation.
Q92865754	Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
Q50522192	Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms.
Q43258274	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Q41445901	Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.
Q57097002	Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression
Q36603665	Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population
Q46173047	Association of ABCB1, CYP3A418B and CYP3A53 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis
Q37727173	Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Q46175794	Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population
Q46796622	Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil
Q41010465	Association of CYP3A5*3 polymorphism with development of acute leukemia
Q36755319	Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome
Q81660032	Association of MDR1, CYP3A418B, and CYP3A53 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients
Q33937239	Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors
Q95801846	Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19
Q46738241	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
Q37359687	Association of genotypes of the CYP3A cluster with midazolam disposition in vivo
Q42759527	Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
Q46480439	Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension
Q43826505	Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia
Q35613163	Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
Q47400081	Associations of the CYP3A53 and CYP3A41G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Q37383940	Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
Q37999484	Atopic dermatitis in African American children: addressing unmet needs of a common disease
Q36814845	Biological interactions of CYP2C19 genotypes with CYP3A418, CYP3A53, and MDR1-3435 in living donor liver transplantation recipients.
Q79227006	Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Q21261465	CLC-2 single nucleotide polymorphisms (SNPs) as potential modifiers of cystic fibrosis disease severity
Q38702659	CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism
Q35972237	CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects
Q33368192	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
Q44273424	CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
Q55341980	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole.
Q47778081	CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia
Q86705745	CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation
Q39675535	CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients
Q28244721	CYP3A phenotypes and genotypes in North Indians
Q37478703	CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation
Q33910537	CYP3A variation and the evolution of salt-sensitivity variants
Q24810187	CYP3A4 and CYP3A5 genotyping by Pyrosequencing
Q33785147	CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease
Q38348695	CYP3A4 and MDR1 alleles in a Portuguese population
Q39534657	CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes
Q39247900	CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.
Q89585264	CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel
Q38068539	CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Q56834660	CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
Q37416133	CYP3A5 and ABCB1 genes and hypertension
Q43087572	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
Q80316046	CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients
Q83171076	CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome
Q46683443	CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population
Q92423027	CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis
Q36704223	CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition
Q44675164	CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers
Q35882638	CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients
Q43946040	CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
Q34360012	CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers
Q52921101	CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.
Q79456645	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
Q44445808	CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults
Q42232484	CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients
Q35933626	CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin
Q36657755	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Q35825323	CYP3A5 phenotype-genotype correlations in a British population
Q36410123	CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease
Q47436945	CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men.
Q42666167	CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
Q38122295	CYP3A5 polymorphism, amlodipine and hypertension
Q55280859	CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.
Q34458070	CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.
Q54766961	CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese.
Q73414003	CYP3A53 and 6 single nucleotide polymorphisms in three distinct Asian populations
Q37104987	CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents
Q86063853	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers
Q35113316	CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children
Q37627774	CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites
Q43046014	CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women
Q44892856	CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer
Q38241677	Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Q38093137	Cancer pharmacogenomics in children: research initiatives and progress to date.
Q36305439	Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
Q34609133	Candidate gene approach for pharmacogenetic studies
Q37422663	Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure
Q84704883	Cardiac arrest and possible seizure activity after vincristine injection
Q35447163	Cardiovascular pharmacogenomics
Q28388277	Causes of genome instability: the effect of low dose chemical exposures in modern society
Q38103767	Challenges in pharmacogenetics
Q44502093	Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
Q47672239	Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism.
Q37603873	Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity
Q24301858	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro
Q35782898	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Q38467280	Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
Q36613862	Clinical application of pharmacogenetics in gastrointestinal diseases
Q54266810	Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Q37527189	Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs
Q37678060	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.
Q36546247	Clinical implications of CYP3A polymorphisms
Q34332261	Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
Q36410396	Clinical pharmacokinetics of docetaxel : recent developments
Q46246088	Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Q31135635	Cloning, tissue distribution, and functional studies of a new cytochrome P450 3A subfamily member, CYP3A45, from rainbow trout (Oncorhynchus mykiss) intestinal ceca
Q39065445	Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population
Q36339420	Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
Q47309313	Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models
Q53005242	Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
Q40282075	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.
Q36700755	Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities
Q36285546	Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer
Q47128107	Comparison of genome sequencing and clinical genotyping for pharmacogenes
Q41107159	Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study
Q39018202	Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients
Q33977228	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.
Q46684824	Concepts of Genomics in Kidney Transplantation
Q33334373	Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs
Q45262234	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy
Q37720189	Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism
Q42515369	Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes
Q33903933	Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response
Q36948123	Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Q34358307	Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance
Q35953101	Cytochrome P450 3A Enzymes Catalyze the O6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine Biosynthesis
Q35564329	Cytochrome P450 3A and their regulation
Q73107525	Cytochrome P450 3A pharmacogenetics: the road that needs traveled
Q36050572	Cytochrome P450 3A polymorphisms and immunosuppressive drugs
Q37074093	Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update
Q41640449	Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib
Q80178773	Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects
Q36406298	Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc
Q36696957	Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer
Q82577163	Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients
Q36426794	Cytochrome P450 pharmacogenetics and cancer.
Q38099372	Cytochrome P450 pharmacogenetics in African populations.
Q37954366	Cytochrome P450 polymorphisms and drug-induced interstitial lung disease
Q34491448	Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations
Q37811619	Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis
Q39003041	Cytochrome and sulfotransferase gene variation in north African populations
Q34706835	Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Q35827133	Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract
Q35036697	Decision tree-based modeling of androgen pathway genes and prostate cancer risk
Q39767486	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity.
Q64056419	Defining the genetic and evolutionary architecture of alternative splicing in response to infection
Q42480303	Determination of a quantitative relationship between hepatic CYP3A51/3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations
Q33574176	Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach
Q39968946	Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs
Q38086777	Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations
Q37841723	Developmental pharmacogenomics
Q35827137	Dexamethasone as a probe for vinorelbine clearance
Q35876954	Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms
Q39132868	Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
Q50179674	Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
Q40658076	Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Q34531479	Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer.
Q45420475	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro
Q37330641	Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether
Q36701911	Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
Q36585295	Disparities in solid organ transplantation for ethnic minorities: facts and solutions
Q37715233	Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective
Q43882753	Diversity of the apoptotic response to chemotherapy in childhood leukemia
Q43791088	Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Q38899401	Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Q55002373	Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Q44600103	Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
Q34475012	Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.
Q34278840	Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate
Q37901060	Drug interactions in African herbal remedies
Q42070178	Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5
Q28472957	Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite
Q38522299	Drug-drug interactions that interfere with statin metabolism
Q44165395	Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort
Q57174194	Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?
Q35753588	Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
Q50540290	Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers
Q43120631	Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety
Q34099716	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Q38604479	Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism.
Q37027004	Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions
Q47920373	Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre
Q46666595	Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects
Q35931626	Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone.
Q85417646	Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation
Q85417587	Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients
Q56834587	Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
Q37611687	Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients
Q46816943	Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients
Q48230143	Effect of breviscapine on CYP3A metabolic activity in healthy volunteers
Q37017426	Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Q46408189	Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects
Q89518814	Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients
Q46307844	Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem
Q53581879	Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.
Q36558437	Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania
Q53581485	Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Q44556926	Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers
Q34606802	Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma
Q90433604	Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites
Q89281958	Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans
Q92840787	Effects of CYP3A4 polymorphisms on efficiency of general anesthesia combined with epidural block in patients undergoing cardiac valve replacement
Q64949735	Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Q39328270	Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies
Q46127207	Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort
Q42204826	Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia
Q90063433	Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
Q51693404	Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Q36884097	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines
Q54576089	Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Q36654010	Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors
Q41704645	Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy
Q46795537	Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
Q34175342	Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study
Q48698266	Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns
Q33251030	Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation
Q34266864	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Q39374368	Ethnic differences in the distribution of CYP3A5 gene polymorphisms
Q36758880	Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes
Q64951799	Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
Q88512035	Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise
Q35796733	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
Q48695639	Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
Q36659874	Expressed sequence tags (ESTs) and single nucleotide polymorphisms (SNPs): what large-scale sequencing projects can tell us about ADME.
Q53526711	Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum.
Q89365886	Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis
Q35196196	Factors affecting the clinical development of cytochrome p450 3A substrates
Q49108837	Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study.
Q37709405	Factors associated with clopidogrel nonresponsiveness
Q28547130	Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial
Q37818297	Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.
Q36750899	Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control
Q42754368	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Q99708872	Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
Q54455073	Frequency of common CYP3A5 gene variants in healthy Polish newborn infants.
Q35666588	From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy
Q28477350	Functional evaluation of genetic and environmental regulators of p450 mRNA levels
Q38220008	Functional gene variants of CYP3A4.
Q92229330	Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle
Q34550483	Functional interactions between P-glycoprotein and CYP3A in drug metabolism
Q28260518	Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
Q52680235	GST CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip.
Q37550556	Gender and interindividual variability in pharmacokinetics.
Q30491768	Gene conversion causing human inherited disease: evidence for involvement of non-B-DNA-forming sequences and recombination-promoting motifs in DNA breakage and repair
Q37664073	Gene conversion in human genetic disease
Q44936834	Gene expression of cytochromes P450 in liver transplants over time
Q38556530	Gene-environment interactions in esophageal cancer
Q48113822	Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients
Q37697779	Genetic causes of clopidogrel nonresponsiveness: which ones really count?
Q28212042	Genetic contribution to variable human CYP3A-mediated metabolism
Q36205840	Genetic diversity and new therapeutic concepts
Q34501025	Genetic factors affecting drug disposition in Asian cancer patients.
Q26823434	Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
Q36802054	Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus
Q53366009	Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients.
Q37218129	Genetic polymorphisms and the fate of the transplanted organ
Q46045922	Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Q44035338	Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups
Q33632608	Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Q83379575	Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians
Q35110430	Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
Q48678969	Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome
Q46420441	Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Q35753607	Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers
Q57091696	Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China: A cohort study
Q40135202	Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 3A5 in a Uyghur Chinese population
Q35566060	Genetic polymorphisms, drugs, and proarrhythmia
Q35941387	Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives
Q34722941	Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes
Q30341330	Genetic variability in CYP3A5 and its possible consequences.
Q36814006	Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma
Q35749331	Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Q35000771	Genetic variation in CYP3A43 explains racial difference in olanzapine clearance
Q46986041	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
Q47820302	Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Q39098740	Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment
Q40732067	Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients
Q47898148	Genetics of acute rejection after kidney transplantation.
Q47436776	Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients
Q47172157	Genome-wide association study of offspring birth weight in 86,577 women identifies five novel loci and highlights maternal genetic effects that are independent of fetal genetics
Q28543477	Genome-wide discovery of drug-dependent human liver regulatory elements
Q37073151	Genome-wide scan for hypertension linkage to chromosome 12q23.1 - q23.3 in a Chinese family
Q36522026	Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles
Q36586562	Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver
Q37009025	Genotype-guided tacrolimus dosing in African-American kidney transplant recipients
Q44600105	Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
Q38429245	Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls
Q38120289	Germline pharmacogenetics of paclitaxel for cancer treatment
Q41774099	Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population
Q38595273	Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome
Q36445096	Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells
Q92248443	Guide to the Assessment of Mature Liver Gene Expression in Stem Cell-Derived Hepatocytes
Q37608527	HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice
Q90731387	HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?
Q46342423	Hepatic expression of cytochrome P450 enzymes in non-human primate species.
Q35202947	Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids
Q36384257	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
Q41918312	Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.
Q34660699	How important are gender differences in pharmacokinetics?
Q24642872	How to calculate the dose of chemotherapy
Q42859467	Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by Ketoconazole
Q35566353	Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Q40571160	Human genetic variation and disease
Q35070838	Human pharmacogenomic variations and their implications for antifungal efficacy
Q45749580	Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance.
Q34546846	Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans
Q52368235	Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Q57224790	Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients
Q46413699	Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone
Q28212945	Identification of the novel splicing variants for the hPXR in human livers
Q89465632	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135)
Q53581058	Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.
Q37947674	Immune factors influencing ethnic disparities in kidney transplantation outcomes
Q37591508	Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions
Q46149716	Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 3/3 non-expressors
Q90549526	Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients
Q34976487	Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Q37646573	Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin
Q46063082	Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India
Q46357849	Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients
Q45279289	Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism
Q87749359	Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease
Q86853519	Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation
Q64945530	Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation.
Q43645616	Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients
Q54586923	Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Q38103593	Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
Q36909306	Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans
Q57163787	Impact of population admixture on the distribution of theCYP3A5*3polymorphism
Q37581626	Impact of rat P450 genetic polymorphism on diazepam metabolism
Q48567513	Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation
Q89435939	Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations
Q52565287	Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
Q37538787	Implementation of CYP2D6 genotyping in psychiatry
Q35918055	Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials
Q34457429	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
Q35111625	In vitro and pharmacophore insights into CYP3A enzymes
Q47940552	In vitro identification of human cytochrome P450 isoforms involved in the metabolism of Geissoschizine methyl ether, an active component of the traditional Japanese medicine Yokukansan
Q42862529	In vitroassessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450enzyme identification, inhibition, and induction studies
Q42979587	In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics.
Q41092089	In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study
Q34568130	Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Q34486506	Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia
Q35013781	Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects
Q35855012	Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations
Q50933157	Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
Q48088487	Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study
Q64243932	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
Q37391731	Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models
Q42246055	Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects
Q54353014	Influence of ABCB1, CYP3A418B and CYP3A53 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Q36474050	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Q49792894	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients
Q45974065	Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
Q46716764	Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression
Q92682760	Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
Q43160188	Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese
Q46690564	Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
Q42795568	Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients
Q57269486	Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients
Q28305304	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam
Q90737574	Influence of POR28 Polymorphisms on CYP3A53-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation
Q40265172	Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Q79939096	Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients
Q89584159	Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population
Q28244228	Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients
Q28293875	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
Q37662992	Influence of tacrolimus metabolism rate on renal function after solid organ transplantation
Q54453864	Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients.
Q36781075	Inherent sex-dependent regulation of human hepatic CYP3A5
Q47314885	Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis.
Q28552997	Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
Q36536037	Interaction between midazolam and clarithromycin in the elderly
Q85940481	Interactions between CYP3A53 and POR28 polymorphisms and lipid lowering response with atorvastatin
Q36618692	Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism
Q45151697	Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity
Q37964574	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes
Q35082735	Interpretation of genetic association studies in complex disease
Q35642257	Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Q41856614	Intronic polymorphisms of cytochromes P450.
Q35804217	Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Q74592025	Islands of linkage disequilibrium
Q34091794	Issues in the treatment of epilepsy
Q56907978	Kidney Transplant Recipients Carrying theCYP3A4*22Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations
Q36099442	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
Q91814753	Lack of Relationship Between Renal Function and Genetic Variants of CYP3A4, CYP3A5, MDR1, MRP2, UGT1A9, UGT1A8, and UGT2B7 in Patients After Liver Transplantation in a 2-Year Follow-up
Q46174011	Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe
Q36803391	Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients
Q34427355	Lactase persistence and lipid pathway selection in the Maasai
Q28387774	Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans
Q44962627	Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone
Q38129422	Lipid-lowing pharmacogenomics in Chinese patients
Q86591874	Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation
Q28481272	Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
Q40750400	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype
Q37137128	Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations
Q43182515	Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism
Q36442886	Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs
Q94076945	MDR1和CYP3A5基因多态性对伊马替尼治疗慢性骨髓性白血病预后的影响
Q35158006	Making better drugs: Decision gates in non-clinical drug development
Q26778504	Maraviroc: a review of its use in HIV infection and beyond
Q40248432	Mass spectral analysis of the multikinase inhibitor BZG and its metabolites and analysis of their binding to vascular endothelial growth factor receptor-2.
Q37776695	Maternal ethnicity influences on neonatal respiratory outcomes after antenatal corticosteroid use for anticipated preterm delivery
Q33683838	Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.
Q44543753	Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test
Q28080497	Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
Q36068699	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Q45916609	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.
Q34660924	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes
Q36776572	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes
Q39582357	Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma
Q36024688	Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
Q47096668	Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology
Q41334556	Molecular basis for prostate cancer racial disparities.
Q34704763	Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa
Q42703436	Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.
Q43952477	Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine
Q37465914	Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine
Q49287982	Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases
Q35784527	Moving towards individualized medicine with pharmacogenomics
Q37126092	Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients
Q34078905	Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction
Q77758106	Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP
Q46678851	NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease
Q57491987	Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response
Q38707932	New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs
Q28477100	Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey
Q33688800	Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic
Q91829800	OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches
Q38834246	One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells
Q34836887	Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.
Q38003479	Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies
Q47144709	Opinion of the scientific panel on contaminants in the food chain [CONTAM] related to the potential increase of consumer health risk by a possible increase of the existing maximum levels for aflatoxins in almonds, hazelnuts and pistachios and deri...
Q37938905	Overview of pharmacogenetics
Q36389312	Overview of the pharmacogenetics of HIV therapy.
Q45018796	P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth
Q79298183	P-glycoprotein increases from proximal to distal regions of human small intestine
Q47546933	P450 Pharmacogenetics in Indigenous North American Populations
Q36551142	PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity
Q36417380	Parsing interindividual drug variability: an emerging role for systems pharmacology
Q35584977	Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism
Q37000474	Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants
Q92127815	Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies
Q33838866	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
Q37182212	PhRMA white paper on ADME pharmacogenomics.
Q33989902	PharmGKB summary: cyclosporine and tacrolimus pathways
Q37081741	PharmGKB summary: very important pharmacogene information for CYP3A5.
Q38787174	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations
Q46075812	Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing
Q47906608	Pharmacogenetic considerations for HIV treatment in different ethnicities: an update
Q37439873	Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients
Q35772582	Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia
Q36544981	Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy
Q52322328	Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.
Q53621686	Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Q35040927	Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs
Q36317007	Pharmacogenetics and anesthesiologists.
Q34572110	Pharmacogenetics and cancer therapy
Q35173693	Pharmacogenetics and clinical gastroenterology
Q37772183	Pharmacogenetics and human genetic polymorphisms
Q36916904	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation
Q37608121	Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes
Q36441485	Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Q38063426	Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.
Q37218086	Pharmacogenetics in solid organ transplantation: current status and future directions
Q38120290	Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs
Q35692680	Pharmacogenetics in the treatment of breast cancer
Q34983633	Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances
Q57163492	Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
Q34733994	Pharmacogenetics of cytotoxic drugs
Q24676890	Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy
Q28249515	Pharmacogenetics of erectile dysfunction: navigating into uncharted waters
Q43155487	Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients
Q37157896	Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients
Q46986763	Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies
Q42143648	Pharmacogenetics of tacrolimus: ready for clinical translation?
Q35067187	Pharmacogenetics of the major polymorphic metabolizing enzymes.
Q50072074	Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety
Q36901492	Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
Q36597343	Pharmacogenetics of warfarin: current status and future challenges
Q34591651	Pharmacogenetics research network and knowledge base: 1st annual scientific meeting
Q23919667	Pharmacogenetics, pharmacogenomics, and individualized medicine
Q34368342	Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
Q35584999	Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation.
Q64077129	Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
Q46726161	Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
Q63169936	Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation
Q28392982	Pharmacogenomic discovery using cell-based models
Q35157989	Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children
Q91829792	Pharmacogenomics And Hypertension: Current Insights
Q36192679	Pharmacogenomics and acquired long QT syndrome
Q28083875	Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population
Q35873676	Pharmacogenomics and stomach cancer.
Q36727952	Pharmacogenomics in pediatric leukemia
Q37419542	Pharmacogenomics of CYP3A: considerations for HIV treatment
Q36634077	Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem
Q27692687	Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Q35127795	Pharmacogenomics of Drugs Affecting the Cardiovascular System
Q60046975	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit
Q57074608	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues
Q38263519	Pharmacogenomics of acetaminophen in pediatric populations: a moving target
Q27015820	Pharmacogenomics of adverse drug reactions
Q35562024	Pharmacogenomics of immunosuppressive drug metabolism
Q37736449	Pharmacogenomics of paclitaxel
Q35654120	Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy
Q37892536	Pharmacogenomics of the triazole antifungal agent voriconazole
Q47664190	Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy
Q38364888	Pharmacogenomics toward personalized tamoxifen therapy for breast cancer
Q35090217	Pharmacogenomics: marshalling the human genome to individualise drug therapy
Q34976915	Pharmacogenomics: the genetics of variable drug responses
Q37978619	Pharmacogenomics: what is next?
Q37724614	Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
Q52859440	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Q36204404	Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.
Q36006086	Pharmacokinetic principles of immunosuppressive drugs.
Q39074126	Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children
Q38520159	Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.
Q35111481	Pharmacokinetics in the newborn
Q44870135	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
Q38055713	Pharmacokinetics of non-intravenous formulations of fentanyl
Q36400412	Pharmacokinetics of tacrolimus during pregnancy
Q47554956	Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Q36134701	Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Q36885663	Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel
Q34057466	Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin
Q39758335	Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes
Q104100069	Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis
Q91438510	Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study
Q88220163	Polymorphism of CYP3A4 2 and eNOS genes in the diabetic patients with hyperlipidemia undergoing statin treatment
Q35035608	Polymorphism of cytochrome P450 and xenobiotic toxicity
Q40126367	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
Q51347270	Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.
Q35620606	Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 Are Associated with Early Age Acute Leukemia
Q43496569	Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
Q46254583	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects
Q37156272	Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
Q28245060	Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia
Q37538683	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals
Q33696563	Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Q37544678	Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi
Q37492036	Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.
Q34609009	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf
Q37175786	Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients
Q46830629	Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients
Q51141067	Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Q43253108	Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
Q39805320	Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation
Q92867615	Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients
Q36410258	Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients
Q36989348	Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy
Q43515674	Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer
Q83940718	Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model
Q57395688	Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase
Q40985493	Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles
Q35859052	Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds
Q37369341	Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
Q80259910	Prediction of systemic exposure to cyclosporine in Japanese pediatric patients
Q36765126	Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients
Q45369421	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Q34146529	Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.
Q27024142	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations
Q36442571	Proximal tubular function and salt sensitivity
Q34949176	Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation
Q92252367	Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions
Q46896462	Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate
Q44438917	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.
Q38178095	Race and ethnicity in cancer therapy: what have we learned?
Q37016344	Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
Q73301280	Recent advances in pharmacokinetics in elderly
Q34604457	Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.
Q34659732	Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis
Q34278794	Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition
Q37406800	Regulation of CYP3A genes by glucocorticoids in human lung cells
Q34906432	Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients
Q41328717	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects
Q34325249	Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Q42592136	Response to "clinical relevance of CYP3A5 genotype on maraviroc exposures".
Q43865209	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Q42340044	Risk factors for drug-induced long-QT syndrome
Q37062637	Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny
Q26798470	Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children
Q93089155	Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis
Q51297212	Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
Q39048761	Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation
Q55497899	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.
Q36249224	Sarcomas and pharmacogenetics
Q51590608	Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.
Q30357429	Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.
Q40925162	Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized
Q28284189	Sequence diversity and haplotype structure at the human CYP3A cluster
Q33710324	Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A53/3
Q58003103	Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
Q34265530	Sex is a major determinant of CYP3A4 expression in human liver
Q51755245	Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.
Q36375323	Significance of the minor cytochrome P450 3A isoforms.
Q46511487	Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients
Q54435691	Significant impacts of CYP3A41G and CYP3A53 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Q43072825	Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch
Q45983549	Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.
Q60895639	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Q85673880	Single nucleotide polymorphism of CYP3A4 intron 2 and its influence on CYP3A4 mRNA expression and liver enzymatic activity in human liver
Q26749011	Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects
Q48276802	Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
Q37521064	Statin regulation of CYP3A4 and CYP3A5 expression
Q33683890	Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex
Q60458901	Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma
Q33419367	Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype
Q38726658	Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
Q44402549	Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms
Q61826550	Tacrolimus Elimination in Four Patients With a CYP3A53/3 CYP3A422/22 Genotype Combination
Q88726021	Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients
Q46919747	Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.
Q44745249	Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism
Q43187743	Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics
Q38840993	Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients
Q37224555	Tamoxifen resistance in breast cancer
Q33444299	The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer
Q35236618	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
Q35897778	The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C1935 and CYP2C192 Alleles
Q46237120	The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density
Q58869670	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients
Q47306662	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients
Q37513374	The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
Q90136673	The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?
Q33335841	The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease
Q43878284	The PXR crystal structure: the end of the beginning
Q33749037	The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients
Q88910051	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics
Q39930066	The Uromodulin Gene Locus Shows Evidence of Pathogen Adaptation through Human Evolution
Q46431720	The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.
Q46304188	The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth
Q92772619	The cellular basis of fetal endoplasmic reticulum stress and oxidative stress in drug-induced neurodevelopmental deficits
Q36229351	The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Q41693100	The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome
Q35618156	The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
Q35827669	The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study
Q39115111	The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia
Q47235654	The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer
Q34741545	The genetic basis of variability in drug responses
Q38976077	The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model
Q38699711	The impact of genetic factors on response to glucocorticoids therapy in IBD.
Q40432523	The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients
Q36925256	The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin
Q44976819	The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).
Q58812374	The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients
Q33628473	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Q37405437	The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans
Q50868889	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
Q36000830	The influence of age and sex on the clearance of cytochrome P450 3A substrates
Q37857285	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation
Q44899003	The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.
Q34076521	The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme
Q60458908	The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran
Q37722744	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.
Q46954039	The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates
Q37646778	The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Q36186945	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
Q34469295	The pharmacogenetics of imanitib
Q38664725	The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review
Q36752662	The pharmacogenetics research network: from SNP discovery to clinical drug response.
Q34574033	The pharmacogenomics of HIV therapy.
Q36286418	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
Q37422747	The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine
Q33521351	The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation
Q38844220	The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients
Q36497088	The role of genetic variability in drug metabolism pathways in breast cancer prognosis
Q37987439	The role of genetics in drug dosing
Q38163945	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Q37400616	The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism
Q36582619	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance
Q36285918	Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Q90111160	Transchromosomic technology for genomically humanized animals
Q37880878	Transcriptional regulation and pharmacogenomics
Q40609924	Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5'-flanking region
Q39175303	Transplant genetics and genomics
Q38195148	Transplantation genetics: current status and prospects
Q33403257	Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations
Q37945308	Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.
Q36013357	Troglitazone and liver injury: in search of answers
Q43979778	UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Q42425352	Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
Q36373816	Update on pharmacogenetics in epilepsy: a brief review.
Q33664128	Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
Q35579020	Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
Q37436398	Use of cell lines in the investigation of pharmacogenetic loci
Q42837771	Using Genetic and Clinical Factors to Predict Tacrolimus Dose in Renal Transplant Recipients
Q37733572	Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
Q46130790	Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients.
Q47704254	Variability in Expression of CYP3A5 in Human Fetal Liver.
Q35809421	Variability of CYP2J2 expression in human fetal tissues
Q36729040	Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study
Q28078232	Vincristine-induced peripheral neuropathy in pediatric cancer patients
Q39062220	Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism
Q35886700	Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis
Q46991204	Vitamin D receptor haplotypes protect against development of colorectal cancer
Q34283903	Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Q47242677	Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant
Q38853651	Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Q90720262	Worsening of Kidney Transplant Function During 2-Year Follow-up Is Associated With the Genetic Variants of CYP3A4, MDR1, and UGT1A9

P356	DOI	10.1038/86882
P698	PubMed publication ID	11279519
P5875	ResearchGate publication ID	12053040

P50	author	Ann K Daly	Q42383270
P2093	author name string	Zhang J
		Boguski MS
		Lin Y
		Assem M
		Yasuda K
		Maurel P
		Wrighton SA
		Venkataramanan R
		Hall SD
		Schuetz E
		Strom S
		Watkins PB
		Thummel K
		Lamba J
		Brimer C
		Schuetz J
		Kuehl P
		Relling M
P2860	cites work	Initial sequencing and analysis of the human genome	Q21045365
		SXR, a novel steroid and xenobiotic-sensing nuclear receptor	Q22003995
		The Sequence of the Human Genome	Q22065842
		The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions	Q24310512
		Characterization of single-nucleotide polymorphisms in coding regions of human genes	Q28138557
		Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis	Q28138570
		Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans	Q28140931
		The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons	Q28141566
		Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver	Q28243581
		Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?	Q28277410
		Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver	Q28280040
		PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing	Q29618564
		Pharmacogenomics: translating functional genomics into rational therapeutics	Q33751829
		Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology	Q33947596
		Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control.	Q34061094
		Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors	Q34429206
		The role of individual human cytochromes P450 in drug metabolism and clinical response	Q35206070
		The regulation of splice-site selection, and its role in human disease	Q35249099
		Association of CYP3A4 genotype with treatment-related leukemia	Q36643196
		CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity	Q38315596
		The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions	Q41030442
		Expression of cytochrome P450 3A in amphibian, rat, and human kidney	Q41631410
		Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450.	Q41741363
		Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.	Q44686949
		16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5.	Q47943662
		Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.	Q51635996
		A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation: Table 1	Q56566320
		Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities	Q59153257
		Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4	Q73052606
		The power of point mutations	Q73344487
		Variations on a theme: cataloging human DNA sequence variation	Q73974914
		Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region	Q77767515
P433	issue	4
P407	language of work or name	English	Q1860
P304	page(s)	383-391
P577	publication date	2001-04-01
P1433	published in	Nature Genetics	Q976454
P1476	title	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P478	volume	27

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

scientific article published in April 2001

Reverse relations